Impact of low molecular weight heparin administration on the clinical course of the COVID-19 disease | Zendy

Burcu Yormaz | Zendy; Dilek Ergün | Zendy; Baykal Tülek | Zendy; Recai Ergün | Zendy; Uğur Arslan | Zendy; Fikret Kanat | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of low molecular weight heparin administration on the clinical course of the COVID-19 disease

Author(s) -

Burcu Yormaz,

Dilek Ergün,

Baykal Tülek,

Recai Ergün,

Uğur Arslan,

Fikret Kanat

Publication year - 2020

Publication title -

turkish journal of medical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.277

H-Index - 27

eISSN - 1303-6165

pISSN - 1300-0144

DOI - 10.3906/sag-2006-184

Subject(s) - medicine , low molecular weight heparin , d dimer , gastroenterology , receiver operating characteristic , heparin , covid-19 , lymphocyte , c reactive protein , area under the curve , disease , inflammation , infectious disease (medical specialty)

Lymphopenia is the most important criterion of mortality and discharging feature for patients infected with coronavirus disease 2019 (COVID-19). This study aimed to investigate the clinical impact of a low molecular weight heparin (LMWH) treatment on the clinical course of COVID-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research